Motley FoolMesoblast shares: Q4 earnings top projections
Ryoncil® uptake has exceeded initial projections The post Mesoblast shares: Q4 earnings top projections appeared first on The Motley Fool Australia.
MESOBLAST LIMITED ORDINARY (MSB) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Google NewsWhy Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L - simplywall.st
Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L simplywall.st
KalkineMesoblast (ASX:MSB): Why Is ASX 200 Watching Its Cell Therapy Milestone?
Highlights Mesoblast has strengthened its financial position through non-dilutive funding while advancing its lead regenerative medicine program. The company has completed enrolment for its pivotal Phase Three chronic low back pain study. Progress across the Healthcare Stocks sector continues drawing attention as clinical milestones approach. Mesoblast has e...
Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L? - simplywall.st
Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L? simplywall.st
ASXReceives FDA BLA Filing Number and Requests Modular Review
other announcement
Mesoblast (ASX:MSB) Strengthens Funding Position Through New Five-Year Credit Facility - Kalkine
Mesoblast (ASX:MSB) Strengthens Funding Position Through New Five-Year Credit Facility Kalkine
Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
other announcement
MSB (ASX:MSB): The Revenue Milestone Keeping This Biotech on Investor Watchlists
Highlights Mesoblast (ASX:MSB) continues attracting attention as commercial sales momentum builds around its flagship therapy. Record quarterly revenue has reinforced confidence in the company's transition toward a commercial-stage business. Growing interest across ASX Midcap Stocks and ASX Healthcare Stocks has placed Mesoblast firmly in the spotlight. Mesoblast continues drawing investor attention as commercial sales momentum builds, highlighting its progress from biotechnology developer to...
Mesoblast (ASX:MSB) ASX 300 Faces a Bigger Commercial Test
Highlights Mesoblast has regained market attention as commercial traction becomes a larger part of its healthcare story. Ryoncil and the broader therapy pipeline are placing execution and adoption under the spotlight. Healthcare stocks are increasingly being judged on commercial proof, cash discipline, and operational delivery. Mesoblast is entering a new phase where commercial delivery, therapy adoption, pipeline progress, and financial discipline are becoming more important than devel...
Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed? - simplywall.st
Mesoblast (ASX:MSB) Is Up 9.2% After Ryoncil’s Near-US$100m Debut And Revascor FDA Progress – Has The Bull Case Changed? simplywall.st
What Is Driving Increased Trading Activity in Mesoblast (ASX:MSB) Stock? - Kalkine
What Is Driving Increased Trading Activity in Mesoblast (ASX:MSB) Stock? Kalkine
Mesoblast and 4DMedical: The Biotech Trend Quietly Reshaping the Market
Highlights Biotechnology has emerged as one of the strongest growth themes in Australia’s share market during 2026. Mesoblast (ASX:MSB) and 4DMedical (ASX:4DX) have attracted attention as healthcare innovation gains momentum. Advances in regenerative medicine and smart diagnostics are reshaping how the market views healthcare growth opportunities. Australia’s share market is witnessing a notable shift as biotechnology steps into the spotlight alongside traditional market leaders. ...
Mesoblast (ASX:MSB) Leads ASX Gainers Following High-Volume Trading Session - Kalkine
Mesoblast (ASX:MSB) Leads ASX Gainers Following High-Volume Trading Session Kalkine
Mesoblast Advances Clinical Path as Market Reassesses Outlook
Highlights Late-stage trial enrolment milestone achieved Long-term outlook shaped by clinical progress Valuation debate continues amid shifting sentiment Mesoblast continues to draw attention after a key clinical milestone in its chronic pain therapy program, with market sentiment reflecting evolving expectations around future outcomes and valuation positioning. Clinical Progress Marks a Key Development Phase Mesoblast (ASX:MSB) has reached a significant point in its late-stage clinical...
Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L - simplywall.st
Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L simplywall.st
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Patient Recruitment Target Achieved in CLBP Pivotal Trial
other announcement
Mesoblast (ASX:MSB) Drives ASX 200 Healthcare Buzz? - Kalkine Media
Mesoblast (ASX:MSB) Drives ASX 200 Healthcare Buzz? Kalkine Media
Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil - simplywall.st
Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil simplywall.st
Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline - simplywall.st
Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline simplywall.st
Down almost 20% this year, how high could Mesoblast shares go?
The forward pipeline is looking promising. The post Down almost 20% this year, how high could Mesoblast shares go? appeared first on The Motley Fool Australia.
Notification regarding unquoted securities - MSB
other announcement
Acquires CAR Platform for Precision-Enhanced Cell Products
other announcement
Why Mesoblast (ASX:MSB) Is Gaining Attention in ASX 200 Healthcare Stocks
Highlights Mesoblast reflected notable activity within the healthcare sector. Biotechnology segment remained central to sector-wide participation. Healthcare companies continued to influence broader ASX indices. Mesoblast activity highlighted developments within the ASX healthcare sector, reflecting biotechnology innovation and evolving market participation across global medical industries. The healthcare and biotechnology sector represents a significant component of Australia’s e...
StockheadHealth Check: ‘We’ve only just started’, Mesoblast tells investors at inaugural show-and-tell
Mesoblast has outlined plans to double initial revenues and develop stem cell drugs for lower back pain, heart failure and ... Read More The post Health Check: ‘We’ve only just started’, Mesoblast tells investors at inaugural show-and-tell appeared first on Stockhead.
Mesoblast (ASX:MSB) ASX 200 Biotech Sector Activity Explained?
Highlights Mesoblast reflects activity within the biotechnology sector. Healthcare innovation companies remain active across equity markets. ASX 200 and ASX 300 include medical research-driven firms. Mesoblast reflects ASX 200 and ASX 300 biotechnology sector activity, highlighting clinical development processes and healthcare innovation participation. The healthcare and biotechnology sector represents a significant component of the Australian equity market, supporting advancements in m...
Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines? - simplywall.st
Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines? simplywall.st
Mesoblast R&D Day Features Commercial & Blockbuster Programs
other announcement
FDA Clears Ryoncil IND for Registration Trial in DMD
other announcement
Mesoblast shares: Ryoncil® underpins strong earnings growth
Mesoblast shares are in focus as Ryoncil® delivers nearly US$100m in sales since launch, fueling future growth initiatives. The post Mesoblast shares: Ryoncil® underpins strong earnings growth appeared first on The Motley Fool Australia.
Ryoncil Net Revenue for the Quarter Increases to US$30.3M
earnings announcement
Mesoblast (ASX:MSB; Nasdaq:MESO) Sets Stage for R&D Day as Ryoncil® Gains Commercial Traction
Highlights Mesoblast has scheduled its inaugural R&D Day on 8 April 2026 in New York City. The company reported H1 FY2026 revenue of US$51.3 million, driven by Ryoncil® launch. Ryoncil® achieved gross sales of US$57.0 million following U.S. commercial rollout. Phase 3 protocol for adult SR-aGvHD treatment finalised after FDA engagement. FY2026 Ryoncil® net revenue guidance projected between US$110 million and US$120 million. In hospital settings where complications can escalat...
Mesoblast (ASX:MSB) Valuation Check As First R&D Day Puts Pipeline And Growth Plans In Focus - simplywall.st
Mesoblast (ASX:MSB) Valuation Check As First R&D Day Puts Pipeline And Growth Plans In Focus simplywall.st
Appendix 3Ys - S Itescu, E Rose, G George and L Cobley
director_dealing announcement
Notification regarding unquoted securities - MSB
other announcement
A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans - simplywall.st
A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans simplywall.st
Appointment of Clinical Development and Medical Affairs Head
other announcement
Replacement Appendix 3Y for Gregory George
capital_raise announcement
Ryoncil Profits Underpinning Substantial Growth Pipeline
earnings announcement
Corporate Presentation and Half Year Financial Results
other announcement
Half Year Report and Accounts (including Appendix 4D)
other announcement
Mesoblast 2026 Half Year Financial Results Webcast
other announcement
High Survival Rates with Ryoncil in SR-aGvHD EIND Program
other announcement